KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (Diluted Average) (2020 - 2025)

Acadia Pharmaceuticals (ACAD) has 9 years of Shares Outstanding (Diluted Average) data on record, last reported at $169.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 2.14% year-over-year to $169.9 million; the TTM value through Dec 2025 reached $169.9 million, up 2.14%, while the annual FY2025 figure was $169.9 million, 2.14% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $169.9 million in Q4 2025 per ACAD's latest filing, roughly flat from $169.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $169.9 million in Q4 2025 and bottomed at $159651.0 in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $122.0 million, with a median of $163.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): skyrocketed 101080.84% in 2023, then grew 0.63% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $160493.0 in 2021, then skyrocketed by 100641.47% to $161.7 million in 2022, then grew by 1.32% to $163.8 million in 2023, then grew by 1.55% to $166.4 million in 2024, then increased by 2.14% to $169.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $169.9 million in Q4 2025, $169.2 million in Q3 2025, and $168.7 million in Q2 2025.